Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6558277 | 1.00 | KCNH2 (0.42) | KCNH2KDM4ELMNALIPGMEN1 | |
| SCHEMBL10661017 | 1.00 | KCNH2 (0.42) | KCNH2KDM4ELMNALIPGMEN1 | |
| SCHEMBL19405573 | 0.98 | KCNH2 (0.39) | KCNH2KDM4ELMNALIPGMEN1 | |
| SCHEMBL24998 | 0.93 | KDM4E (0.35) | KCNH2KDM4ELMNAMEN1KMT2A | |
| SCHEMBL9322491 | 0.85 | LMNA (0.31) | KDM4ELMNATSHR | |
| SCHEMBL21523367 | 0.80 | LIPG (0.49) | KCNH2LIPGMEN1KMT2ATP53 | |
| SCHEMBL21523356 | 0.80 | LIPG (0.49) | KCNH2LIPGMEN1KMT2ATP53 | |
| SCHEMBL21523328 | 0.80 | LIPG (0.49) | KCNH2LIPGMEN1KMT2ATP53 | |
| SCHEMBL21523330 | 0.80 | LIPG (0.49) | KCNH2LIPGMEN1KMT2ATP53 | |
| SCHEMBL21523355 | 0.80 | LIPG (0.49) | KCNH2LIPGMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107004906-B | Magnesium-containing electrolyte | 富士胶片和光纯药株式会社 | 2020-04-21 | — | — | CN | disclosed |
| US-10367231-B2 | Magnesium-containing electrolytic solution | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-07-30 | — | — | US | disclosed |
| EP-3226340-B1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20170331154-A1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| EP-3226340-A1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | Wako Pure Chemical Industries, Ltd. (JP) | 2017-10-04 | — | — | EP | disclosed |
| EP-2588480-A2 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF& xA; | SANOFI (FR) | 2013-05-08 | — | — | EP | disclosed |
| WO-2011161537-A2 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10367231-B2 | Magnesium-containing electrolytic solution | CA1, CA3, CA2 | KCNH2 67/4885KDM4E 3595/4885LMNA 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.